🌟Introducing the advisory board for ASCO AI in Oncology:
🔹Editor-in-Chief Ravi B. Parikh, MD, MPP, FACP
🔹Kenneth L. Kehl, MD, MPH
🔹Danielle S. Bitterman, MD
🔹Travis Zack, MD, PhD
🔹Jame Abraham, MD, FACP
https://ascoai.org/editorial-advisory-board/
New computational biomarker (TmS) may better predict chemotherapy response in pts with triple-negative breast cancer than current methods; identified high-TmS (favorable) vs low-TmS (poor prognosis) groups.
🔸 Wenyi Wang, PhD | Cell Reports Medicine
Learn more ➡️ https://ow.ly/JXhx50YmrR0
💻 ASCO AI: Can federated learning accelerate precision oncology?
The Cancer AI Alliance is training #AI models across 4 NCI cancer centers—without sacrificing patient privacy.
📝️ Interview with Eliezer Van Allen, MD
🔗 https://ow.ly/N31j50YmEQW
🆕 The February issue of The ASCO Post is LIVE! This issue features: highlights from GI 2026, ASH 2025, ESMOAI 2025; an interview with Kimmie Ng, MD on early-onset GI cancers; perspectives on AML treatment shifts; and MORE!
Read the full issue 👉 https://ascopost.com/issues/february-25-2026/
🧠 New AI deep learning approach (M-PACT) may enable the identification and classification of pediatric brain tumors from a liquid biopsy using cerebrospinal fluid.
✍️ Katie Han & Kyle Smith, PhD of St. Jude Children's Research Hospital | Nature Cancer
🔗 https://ow.ly/Lr5H50Yl51r
📢 Zsofia K. Stadler, MD, has been named the next Editor-in-Chief of JCO Precision Oncology. A leader in cancer genetics and tumor-normal sequencing, she will guide the journal as genomics and AI reshape precision oncology.
🔗 https://ow.ly/m4T250YklUm
🖥️ In advanced pancreatic cancer, a histomorphology-based AI biomarker identified patients more likely to benefit from gemcitabine- vs fluoropyrimidine-based chemo
🩸 Biomarker–treatment interaction significant for TNTD & OS
✍️ Andrew E. Hendifar, MD
🔗 https://ow.ly/LuSg50YiYYM
🫁 #ASCOAI: With gaps in molecular testing rates, AI may expand access to clinical decision-making tools.
Deep-learning models detected EGFR, ALK, BRAF, MET alterations in lung cancer from H&E slides.
👨⚕️ Christian Rolfo, MD, PhD
🔗 https://ow.ly/VLQM50YhS7W
🧠 Early data in glioblastoma: A single injection of a herpes simplex virus triggered sustained antitumor T-cell responses, with immune infiltration linked to clinical benefit.
✍️ Kai Wucherpfennig, MD, PhD & E. Antonio Chiocca, MD, PhD
🔗 https://ow.ly/wM8r50YhGoA
💻 Explore the new ASCO AI in Oncology
Clifford A. Hudis, MD, FACP, FASCO, shares how this new digital hub delivers broad coverage of AI in cancer care—featuring curated AI research, clinical insights, and expert perspectives for oncology professionals.
https://ow.ly/bx5P50Yhg0G
🫀AI meets cardio-oncology. The ONCO-ACS risk model improves prediction of CV death, MI, and ischemic stroke in patients with cancer and heart disease. A step toward more personalized secondary prevention.
Senior author: Thomas F. Lüscher, MD
🔗 https://ow.ly/qVGS50Yfbxq
In an interview with American Society of Clinical Oncology CEO Clifford Hudis, Dr. Hudis introduces ASCO AI in Oncology (ascoai.org), the new digital platform dedicated to understanding how AI is impacting cancer care.
https://ascoai.org/articles/2026/02/introducing-asco-ai-in-oncology/
📢 ASCO in collaboration with Conexiant today announced the launch of ASCO AI in Oncology (https://ow.ly/tiak50Ycj11), a new digital destination focused on delivering curated content and education around the evolving role of AI in cancer care.
https://ow.ly/WqaG50Ycj10
🏥 American College of Surgeons released its annual National Cancer Database report, showing a major rise in neoadjuvant systemic therapy across cancer types—helping shrink tumors, guiding treatment decisions, & enabling less invasive surgery.
Read key takeaways 👉 https://ow.ly/iqfp50Y8NI7
🗣️ Matthew Strickland, MD, discusses phase IIb TERRIFIC data evaluating neoadjuvant tislelizumab + chemoradiotherapy vs chemo(radio)therapy for patients with locally advanced gastric/GEJ adenocarcinoma.
🎥 Watch the video: https://ow.ly/LcNf50Y7JNK
🚨 Cancer workforce shortages threaten patient access & research progress, according to a report from the President’s Cancer Panel.
🔹Report by Mitchel S. Berger, MD & Carol L. Brown, MD
Learn about recommendations for addressing shortages 👉 https://ow.ly/nEeA50Y5oX2
🚨 New American Cancer Society study: States that limit/don’t allow short-term health plans saw delays in timely cancer treatment initiation after diagnosis. Health insurance is a major factor in survival. #CancerCare
✍️ Jingxuan Zhao, PhD
🔗 https://ow.ly/kPMk50Y4UpZ
🧠 Targeted therapy shows activity in aggressive meningiomas.
In a phase II Alliance trial, abemaciclib slowed tumor growth in patients with NF2 mutations or CDK pathway–altered meningiomas.
Priscilla Brastianos, MD
🔗 https://ow.ly/4ZCp50Y3UoA
🕊️ “A Battle With My Blood” - the final essay by Tatiana Celia Kennedy Schlossberg, recounting her diagnosis with aggressive acute myeloid leukemia and her search for meaning, hope, and memory.
https://ascopost.com/issues/january-25-2026/a-battle-with-my-blood/
🆕 The January 2026 issue of The ASCO Post features: highlights from ASH 2025, SABCS 2025, and GI 2026; and an essay written by Tatiana Schlossberg about her battle with AML reprinted following her death.
Don’t miss this issue 👉 https://ascopost.com/issues/january-25-2026/
📢 The FDA has issued a draft guidance for the use of minimal residual disease and complete response as endpoints in multiple myeloma clinical trials to support accelerated approval.
https://ow.ly/Q5bc50Y1n9K
⚖️💊 FDA & EMA set global principles for good, responsible AI use in drug development.
New guidance outlines 🔟 best practices to ensure AI tools support safe, ethical, and effective drug innovation.
Read the full list of principles here 👉 https://ow.ly/C9Ka50Y0BC0
📊American Cancer Society’s Cancer Stats, 2026:
⬆️ 5-yr survival rate for all cancers = 70%
⬆️ Significantly increased 5-yr survival rates: multiple myeloma, liver cancer, metastatic melanoma, regional lung cancer
⬇️ Mortality rate dropped by 34% through 2023
https://ow.ly/bukz50Y0gX9
🥫 Study highlights possible links between select food preservatives and cancer risk:
• Potassium sorbate, potassium nitrate, total acetates → ⬆️ overall & breast cancer risk
• Sodium nitrite → ⬆️ prostate cancer risk
🔹Hasenböhler et al |
https://ow.ly/oJlT50XWc7r
📊 Final data from phase III AGO-OVAR 2.29:
No significant OS or PFS benefit with atezolizumab + bevacizumab + nonplatinum chemo in recurrent ovarian cancer, though a paclitaxel subgroup showed a favorable OS signal.
🔸 Philipp Harter, MD
🔗 https://ow.ly/PYjn50XVIWN
🔬COMMIT trial shows triplet therapy (FOLFOX + bevacizumab + atezolizumab) significantly improved PFS vs atezolizumab alone in 1L dMMR/MSI-H mCRC (HR = 0.43)
• 12-mo PFS: 67% vs 35%
Caio Max Sao Pedro Rocha Lima, MD, MS
🔗 https://ow.ly/Mpgl50XT5Yw
🍔A study found higher fast-food spending by block in Alabama was linked to more cases of early-onset colorectal cancer, while higher fruit & vegetable spending had a strong protective effect.🥦
🔹 Blake Buchalter, MPH, PhD
🔗 https://ow.ly/urH650XT29I
🔮 The path forward isn’t AI instead of clinicians—but human+AI collaboration, according to Michael Sobolev, PhD et al.
🔹 Public trust, including for AI’s role in #cancer detection (currently ~15% of survey respondents), grows with experience.
🔗 https://ow.ly/EOYs50XS1A7
🔬Postoperative ctDNA testing may help personalize adjuvant therapy in patients with colon cancer—identifying those most likely to benefit from NSAIDs like celecoxib added to chemotherapy.
👨⚕️ George Q. Zhang, MD, MPH
🔗 https://ow.ly/XuPs50XS1p3
📊Phase III inMIND trial: Adding tafasitamab to lenalidomide + rituximab significantly improved PFS in patients with relapsed/refractory Follicular Lymphoma (22.4 vs 13.9 months; HR = 0.43).
🔺Laurie H. Sehn, MD
🔗 https://ow.ly/PYBQ50XS1kF
